ClinicalTrials.gg
RecruitingNCT07392476Updated Oct 6, 2026

Continuous Glucose Monitoring in Polycystic Ovarian Syndrome

An observational study in Polycystic Ovarian Syndrome (PCOS), sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Planned enrollment
23rd of 35
40 · median 65
Started
2025
with 5 others
Observational
37 of 183
8 open now
Primary completion
2026-12
later than 24 of 41 live
Registered
178th of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 23rd largest by planned enrollment of the 35 observational ones that give a count, is one of 6 that started in 2025, is one of 37 observational ones, reaches primary completion later than 24 of the 41 other live ones, and was the 178th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about blood sugar control in polycystic ovarian syndrome.

The patient will be asked to wear a continuous glucose monitor (CGM) device that is applied to the arm with a sensor or filament that goes under the skin to measure your sugar levels. The patient will wear this at certain time points throughout the study. There will have a total of 2 blood draws (about 1 tsp. of blood) at screening and the 6-month visit, a measure of the patients body muscle and fat (body composition), and fill out a questionnaire at the end of the first 3 months and 6 months.

Study participation in the research will last about 6 months.

03

Conditions studied

  • Polycystic Ovarian Syndrome (PCOS)
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with polycystic ovarian syndrome (PCOS).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult 18-45 years old
  2. Diagnosis of PCOS by usual clinical method such as by Rotterdam criteria
  3. >25 kg/m2

Exclusion criteria

Exclusion Criteria

  1. Currently on medications that can improve glucose levels such as metformin and glucagon like receptor 1 agonists (GLP1RA) or on medications taken for the purpose of weight loss such as phentermine, topiramate, and bupropion.
  2. Previously intake of above-mentioned medications and less than 3 months since last intake of metformin or weight loss medications, and less than 6 months since last intake of GLP1RA
  3. Currently on insulin
  4. Does not have Stelo-compatible phone
  5. Fasting glucose >100 mg/dL (because that is the cutoff for prediabetes) (either labs taken within a week after first visit or within 3 months before start of study
  6. > 5.7% (because this is the cutoff for prediabetes) (either labs taken after screening visit or within 3 months before start of study)
  7. History of anorexia or bulimia
  8. Current or previous CGM use
  9. Use of oral at time of enrolment
  10. Intent to become pregnant within 6 months (will need to terminate study if gets pregnant as glucose readings will be affected)
  11. Menopausal women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Polycystic Ovarian Syndrome

    Patients with Polycystic Ovarian Syndrome

    Device: Stelo glucose biosensor by Dexcom

Interventions

  • DeviceStelo glucose biosensor by Dexcom

    Unblinded continuous glucose monitoring (CGM) system

06

What researchers measure

Primary outcomes

  1. Continuous Glucose measure derived glucometrics

    To describe CGM-derived glucometrics in patients with PCOS before and after lifestyle modification and/or pharmacologic intervention.

    Time frame: 6 months

  2. Continuous Glucose measure derived glucometrics and Polycystic ovarian syndrome

    To explore associations between CGM-derived glucometrics and PCOS-related clinical markers such as anti-mullerian hormone (AMH), HbA1c, lipid levels, body mass index, and body composition. Associations between glucometrics and PCOS-related clinical markers will be evaluated using correlations, two-sample t-tests or Pearson chi-square tests, as appropriate.

    Time frame: 6 months

  3. Lifestyle behaviors

    To evaluate patient perception of CGM in influencing lifestyle behaviors. The survey includes 5 multiple choice questions and will be summarized using frequencies and percentages.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Feb 6, 2026
StartActual
Dec 24, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Aug 15, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 6, 2026
Sites
Cleveland Clinic is now Recruiting
Oct 6, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedCurrently on medications that can improve glucose levels such as metformin and glucagon- like receptor 1 agonists (GLP1RA) or on medications taken for the purpose of weight loss such as phentermine, topiramate, and bupropion.
  • EditedPreviously intake of above-mentioned medications butand less than 3 months since last intake of metformin or weight loss medications, and less than 6 months since last intake of GLP1RA
Oct 6, 2026
Contact
Study contact now listed: added d•••@ccf.org · •••8354. See the current contact
Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cleveland Clinic · Cleveland, United StatesContact added H•••@ccf.org · •••3001
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Recruiting
    Cleveland Clinic is now Recruiting
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedCurrently on medications that can improve glucose levels such as metformin and glucagon- like receptor 1 agonists (GLP1RA) or on medications taken for the purpose of weight loss such as phentermine, topiramate, and bupropion.
    • EditedPreviously intake of above-mentioned medications butand less than 3 months since last intake of metformin or weight loss medications, and less than 6 months since last intake of GLP1RA
    Contact Study contact now listed: added d•••@ccf.org · •••8354. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cleveland Clinic · Cleveland, United StatesContact added H•••@ccf.org · •••3001
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07392476
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Dec 24, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Andrea Parianos, MS
Contact
debsa@ccf.org
216-445-8354

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion